file1
,
file2
, etc. all in the same folder or directory;
first, locate one of the files with the [Browse...] button. Then alter the
file path in the box above to include '*' character (eg. file*
).
Wildcard '?' to blanket only one character works too.Historiographs |
Grand Totals: LCS 22468, GCS 115717, CR 77292 Collection span: - 1979 | |
Word(i) List (5588) Word count: 40313, All words count: 56680 |
# | Word | Recs | TLCS | TGCS |
---|---|---|---|---|
201 | COMPLICATION | 27 | 89 | 378 |
202 | GROWTH | 27 | 51 | 467 |
203 | PASSIVE | 27 | 109 | 501 |
204 | POST-TRANSPLANT | 27 | 44 | 388 |
205 | RECURRENCE | 27 | 92 | 1010 |
206 | UREMIA | 27 | 93 | 833 |
207 | BILATERAL | 26 | 91 | 510 |
208 | COURSE | 26 | 60 | 207 |
209 | PULMONARY | 26 | 90 | 559 |
210 | TRANSPLANTABLE | 26 | 7 | 496 |
211 | ALLOGRAFTED | 25 | 117 | 460 |
212 | FLOW | 25 | 153 | 492 |
213 | HYPERPARATHYROIDISM | 25 | 152 | 1107 |
214 | METABOLISM | 25 | 84 | 391 |
215 | MICE | 25 | 12 | 300 |
216 | REJECTING | 25 | 73 | 549 |
217 | TIME | 25 | 30 | 126 |
218 | CASE-REPORT | 24 | 23 | 390 |
219 | DIAGNOSTIC | 24 | 15 | 96 |
220 | FATE | 24 | 74 | 299 |
221 | HOMOTRANSPLANT | 24 | 254 | 730 |
222 | HYPERLIPIDEMIA | 24 | 32 | 494 |
223 | INVITRO | 24 | 29 | 280 |
224 | PROSPECTIVE | 24 | 70 | 520 |
225 | QUANTITATIVE | 24 | 33 | 166 |
226 | SODIUM | 24 | 48 | 201 |
227 | ANGIOGRAPHY | 23 | 81 | 243 |
228 | CARCINOMA | 23 | 39 | 477 |
229 | COAGULATION | 23 | 157 | 529 |
230 | DIABETES | 23 | 32 | 227 |
# | Word | Recs | TLCS | TGCS |
231 | FACTOR | 23 | 20 | 201 |
232 | INDUCED | 23 | 26 | 493 |
233 | ISCHEMIA | 23 | 85 | 325 |
234 | LEVELS | 23 | 33 | 462 |
235 | MULTIPLE | 23 | 45 | 325 |
236 | RENAL-DISEASE | 23 | 31 | 251 |
237 | RENIN | 23 | 139 | 436 |
238 | SEVERE | 23 | 35 | 244 |
239 | SURGERY | 23 | 36 | 213 |
240 | DRAINAGE | 22 | 40 | 284 |
241 | HEPATITIS-B | 22 | 48 | 289 |
242 | POSSIBLE | 22 | 84 | 458 |
243 | PROTEINURIA | 22 | 71 | 233 |
244 | RUPTURE | 22 | 84 | 284 |
245 | SCINTIGRAPHY | 22 | 9 | 39 |
246 | SERIAL | 22 | 109 | 367 |
247 | TRIAL | 22 | 126 | 543 |
248 | TUMOR | 22 | 7 | 716 |
249 | CYCLOPHOSPHAMIDE | 21 | 35 | 168 |
250 | GASTROINTESTINAL | 21 | 136 | 588 |
251 | MECHANISMS | 21 | 53 | 448 |
252 | MIGRATION | 21 | 93 | 213 |
253 | NEPHROPATHY | 21 | 6 | 163 |
254 | OSTEODYSTROPHY | 21 | 113 | 772 |
255 | PRIOR | 21 | 27 | 178 |
256 | PROGRAM | 21 | 54 | 256 |
257 | RABBITS | 21 | 50 | 231 |
258 | RELATION | 21 | 67 | 378 |
259 | SPONTANEOUS | 21 | 88 | 313 |
260 | UROLOGICAL | 21 | 265 | 748 |
# | Word | Recs | TLCS | TGCS |
261 | ALG | 20 | 100 | 271 |
262 | CELL-MEDIATED | 20 | 69 | 291 |
263 | COMBINED | 20 | 20 | 209 |
264 | DRUGS | 20 | 228 | 912 |
265 | ENHANCED | 20 | 88 | 587 |
266 | EVIDENCE | 20 | 53 | 749 |
267 | EXTRACORPOREAL | 20 | 48 | 210 |
268 | FIRST | 20 | 104 | 211 |
269 | GRAFTED | 20 | 63 | 326 |
270 | GROUP | 20 | 237 | 767 |
271 | HOMOLOGOUS | 20 | 108 | 372 |
272 | ISOLATED | 20 | 72 | 1174 |
273 | METHYLPREDNISOLONE | 20 | 70 | 376 |
274 | PATTERNS | 20 | 46 | 252 |
275 | REFERENCE | 20 | 161 | 655 |
276 | RENALE | 20 | 83 | 192 |
277 | TWINS | 20 | 299 | 1086 |
278 | VIRUS | 20 | 72 | 1008 |
279 | ALLOGENEIC | 19 | 82 | 366 |
280 | CANCER | 19 | 101 | 1058 |
281 | CYTOTOXICITY | 19 | 127 | 1925 |
282 | EXPERIENCES | 19 | 209 | 751 |
283 | FINDINGS | 19 | 27 | 195 |
284 | FOLLOW-UP | 19 | 70 | 276 |
285 | HEPATIC | 19 | 124 | 518 |
286 | HOMOTRANSPLANTED | 19 | 332 | 696 |
287 | HOSPITAL | 19 | 13 | 87 |
288 | IMPORTANCE | 19 | 39 | 247 |
289 | IN-VITRO | 19 | 40 | 136 |
290 | INCIDENCE | 19 | 130 | 1065 |
# | Word | Recs | TLCS | TGCS |
291 | LYMPHOCELE | 19 | 75 | 201 |
292 | PITUITARY | 19 | 11 | 483 |
293 | PLASMA-RENIN | 19 | 36 | 188 |
294 | POTENTIAL | 19 | 26 | 153 |
295 | PRELIMINARY | 19 | 81 | 485 |
296 | PREVENTION | 19 | 90 | 406 |
297 | PROGNOSIS | 19 | 77 | 805 |
298 | PROGNOSTIC | 19 | 39 | 168 |
299 | PROGRESSIVE | 19 | 71 | 414 |
300 | REACTIVITY | 19 | 37 | 168 |
301 | SARCOMA | 19 | 52 | 1151 |
302 | SPLENECTOMY | 19 | 73 | 351 |
303 | SURVEY | 19 | 25 | 274 |
304 | UNUSUAL | 19 | 9 | 113 |
305 | ADMINISTRATION | 18 | 79 | 343 |
306 | ALTERATIONS | 18 | 137 | 336 |
307 | BLOOD-FLOW | 18 | 18 | 182 |
308 | DEGRADATION | 18 | 45 | 150 |
309 | DEPOSITS | 18 | 58 | 204 |
310 | DETERMINATION | 18 | 56 | 613 |
311 | DISORDERS | 18 | 46 | 321 |
312 | DYSFUNCTION | 18 | 52 | 325 |
313 | END-STAGE | 18 | 36 | 205 |
314 | FIBRINOGEN | 18 | 114 | 330 |
315 | GRAFT-SURVIVAL | 18 | 7 | 199 |
316 | INCREASED | 18 | 63 | 794 |
317 | INDUCTION | 18 | 43 | 352 |
318 | MAINTENANCE | 18 | 27 | 318 |
319 | ONE | 18 | 87 | 371 |
320 | PARATHYROIDECTOMY | 18 | 72 | 780 |
# | Word | Recs | TLCS | TGCS |
321 | STEROIDS | 18 | 20 | 154 |
322 | TOLERANCE | 18 | 112 | 688 |
323 | URINARY-TRACT | 18 | 15 | 224 |
324 | ABNORMALITIES | 17 | 47 | 269 |
325 | ANASTOMOSIS | 17 | 12 | 115 |
326 | ANGIOGRAPHIC | 17 | 125 | 289 |
327 | COMPLICATING | 17 | 132 | 597 |
328 | CONTROLLED | 17 | 97 | 741 |
329 | IGG | 17 | 34 | 103 |
330 | IMMUNOLOGIC | 17 | 385 | 1122 |
331 | IMMUNOSUPPRESSED | 17 | 68 | 806 |
332 | IMPROVEMENT | 17 | 38 | 466 |
333 | INTRAVENOUS | 17 | 36 | 248 |
334 | OCULAR | 17 | 29 | 217 |
335 | POSITIVE | 17 | 219 | 1205 |
336 | POST | 17 | 8 | 40 |
337 | PRODUCTS | 17 | 55 | 194 |
338 | REGULAR | 17 | 14 | 91 |
339 | SINGLE | 17 | 33 | 168 |
340 | SPLEEN | 17 | 53 | 249 |
341 | SUPPRESSION | 17 | 120 | 553 |
342 | TUMORS | 17 | 14 | 234 |
343 | URINARY-EXCRETION | 17 | 16 | 114 |
344 | AUSTRALIA | 16 | 82 | 285 |
345 | BASEMENT-MEMBRANE | 16 | 40 | 410 |
346 | BLOCKING | 16 | 58 | 179 |
347 | BONE-MARROW | 16 | 18 | 337 |
348 | CIRCULATING | 16 | 28 | 199 |
349 | CYTOMEGALOVIRUS-INFECTION | 16 | 75 | 964 |
350 | DATA | 16 | 61 | 249 |
# | Word | Recs | TLCS | TGCS |
351 | ERYTHROPOIETIN | 16 | 49 | 248 |
352 | INDEX | 16 | 34 | 215 |
353 | PERIOD | 16 | 125 | 353 |
354 | PREDICTION | 16 | 24 | 132 |
355 | PREDNISONE | 16 | 75 | 430 |
356 | REACTIONS | 16 | 78 | 423 |
357 | RECURRENT | 16 | 24 | 351 |
358 | ACCELERATED | 15 | 35 | 259 |
359 | ACID | 15 | 39 | 138 |
360 | ALDOSTERONE | 15 | 34 | 209 |
361 | ARTERY | 15 | 36 | 188 |
362 | ASSOCIATION | 15 | 89 | 514 |
363 | CAUSE | 15 | 118 | 275 |
364 | CYTOMEGALO-VIRUS | 15 | 2 | 629 |
365 | DELAYED | 15 | 75 | 293 |
366 | DISTRIBUTION | 15 | 83 | 374 |
367 | FISTULA | 15 | 88 | 349 |
368 | HIGH | 15 | 40 | 306 |
369 | HYPERTENSIVE | 15 | 34 | 493 |
370 | IMMEDIATE | 15 | 74 | 171 |
371 | IMPROVED | 15 | 119 | 595 |
372 | LOCAL | 15 | 67 | 302 |
373 | MODIFICATION | 15 | 83 | 383 |
374 | MORBIDITY | 15 | 44 | 119 |
375 | SECRETION | 15 | 38 | 210 |
376 | SPECIAL | 15 | 115 | 466 |
377 | STEROID | 15 | 19 | 127 |
378 | THROMBOSIS | 15 | 22 | 111 |
379 | TOTAL | 15 | 66 | 305 |
380 | ULTRASOUND | 15 | 41 | 362 |
# | Word | Recs | TLCS | TGCS |
381 | UROLOGIC | 15 | 61 | 280 |
382 | ADENOCARCINOMA | 14 | 8 | 356 |
383 | AGENTS | 14 | 79 | 487 |
384 | ALLOGRAFT-REJECTION | 14 | 10 | 263 |
385 | ANESTHESIA | 14 | 14 | 52 |
386 | ASEPTIC | 14 | 76 | 459 |
387 | AVASCULAR | 14 | 52 | 343 |
388 | CHILD | 14 | 49 | 333 |
389 | CONTROL | 14 | 29 | 132 |
390 | CULTURES | 14 | 59 | 152 |
391 | DEMONSTRATION | 14 | 25 | 194 |
392 | DIABETES-MELLITUS | 14 | 34 | 466 |
393 | DISSEMINATED | 14 | 54 | 659 |
394 | DONOR-SPECIFIC | 14 | 37 | 143 |
395 | EVOLUTION | 14 | 29 | 85 |
396 | FIBRIN | 14 | 86 | 269 |
397 | FUNGAL | 14 | 123 | 856 |
398 | HYPERCALCEMIA | 14 | 79 | 342 |
399 | INCOMPATIBILITY | 14 | 151 | 455 |
400 | ISCHEMIC | 14 | 28 | 163 |